RWLK REWALK ROBOTICS LTD

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against ReWalk Robotics Ltd and Encourages Investors with Losses to Contact the Firm

Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against ReWalk Robotics Ltd (“ReWalk” or the “Company”) (Nasdaq: RWLK). Investors who purchased or otherwise acquired ReWalk shares pursuant and/or traceable to the Company’s Stock Offering on or about September 12, 2014 are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that during the Class Period, the Registration Statement and Prospectus issued regarding the Initial Public Offering did not disclose material information, including that ReWalk did not comply with “special controls” requirements.

When this information was revealed to the investing public, the value of ReWalk fell, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
07/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilitie...

Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors IP and technology acquisition is expected to be highly accretive and to advance Lifeward’s position as a diversified biomedical innovation companyWill Expand Lifeward’s portfolio beyond lower-limb solutions, creating a differentiated, whole-body neuro-rehabilitation portfolio Will Strengthen long-term strategic networks with neuro-rehabilitation prescribers, rehabilitation networks, and payers HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- L...

 PRESS RELEASE

Lifeward Announces Reverse Share Split

Lifeward Announces Reverse Share Split Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced that effective with the open of the market on February 24, 2026, the Company will complete a 1-for-12 reverse split of its ordinary shares. On Janu...

 PRESS RELEASE

Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage...

Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton Together, these three national Medicare Advantage insurers represent approximately 16 million beneficiaries across the United States HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global lead...

 PRESS RELEASE

Lifeward Enters Transformative Strategic Investment and Partnership Ag...

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed’s clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportuni...

 PRESS RELEASE

Lifeward Appoints Bob Marshall as Chairman of the Board

Lifeward Appoints Bob Marshall as Chairman of the Board MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- ., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. “On behalf of the Board and e...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch